Explainer
Alzheimer's disease explained: diagnosis, blood tests and new drugs
Alzheimer's disease is a progressive brain disorder and the most common cause of dementia; amyloid plaques and tau tangles are its main features.[1][2][3] Doctors diagnose it with memory tests, scans and biomarker tests, and in 2025 FDA cleared the first blood tests to help detect Alzheimer's pathology.[4][5][6] No treatment cures it. The anti-amyloid antibodies lecanemab and donanemab modestly slowed decline in randomised trials of people with early disease, but they carry a boxed warning for brain swelling and bleeding (ARIA).[7][8][9][10]
This page explains Alzheimer’s disease and the evidence behind its tests and treatments. It is not medical advice. If you or someone close to you has memory problems, talk to a clinician, who can look for treatable causes and discuss whether any test or treatment fits. This page gives no dosing information: that belongs to the prescriber and the official prescribing information.
Alzheimer’s disease is a progressive brain disorder that slowly destroys memory and thinking skills and eventually the ability to carry out simple tasks. Symptoms usually first appear later in life.[1] The National Institute on Aging (NIA) says estimates vary, but more than 6 million Americans may have it. It is the seventh leading cause of death in the US and the most common cause of dementia in older adults.[2]
What happens in the brain
Amyloid plaques and tau tangles are still considered the main features of Alzheimer’s, along with the loss of connections between neurons.[3] WHO says 57 million people were living with dementia worldwide in 2021, with nearly 10 million new cases a year, and Alzheimer disease is the most common form.[11] WHO also says dementia is more common after 65 but is not an inevitable part of ageing. Its listed risk factors include high blood pressure, diabetes, obesity, depression, hearing and vision loss, smoking, harmful alcohol use, physical inactivity and social isolation.[12]
How Alzheimer’s is diagnosed
To diagnose Alzheimer’s, doctors may take a history, test memory, attention and language, order standard lab tests to rule out other causes, measure Alzheimer’s-related proteins in cerebrospinal fluid, and use CT, MRI or PET brain scans.[4] The same tests can find other causes of memory problems, some of which may be treatable and possibly reversible.[13]
Before the early 2000s, Alzheimer’s could only be confirmed at autopsy. Biomarker tests now show signs of the disease in living people.[14] Amyloid PET scans can show plaques, often years before symptoms, but FDA notes they are costly and time-consuming and expose patients to radiation.[15]
The new blood tests
On 16 May 2025 FDA cleared the first blood test used in diagnosing Alzheimer’s: Fujirebio’s Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, for adults 55 and older with signs and symptoms of the disease.[5] In the 499-sample study FDA reviewed, 91.7% of people with a positive result had amyloid plaques on PET or spinal fluid testing, and 97.3% with a negative result had none. Under 20% got an indeterminate result.[16] FDA says the test is for patients seen in specialised care, is not a screening or stand-alone diagnostic test, and carries a risk of false positive and false negative results.[17]
On 8 October 2025 FDA cleared Roche’s Elecsys pTau181 blood test to aid the initial assessment of people aged 55 and older with cognitive decline. Trade press, reporting Roche’s announcement, describe it as the first blood-based Alzheimer’s biomarker test for primary care.[6] Roche reported that in a 312-person study the test had a 97.9% negative predictive value for ruling out Alzheimer’s pathology, the figure also given in FDA’s clearance summary.[18] NIA says blood test results alone should not be used to diagnose dementia.[14]
Treatments: symptom drugs and anti-amyloid antibodies
No known treatment cures Alzheimer’s. Cholinesterase inhibitors such as donepezil, rivastigmine and galantamine are prescribed for mild to moderate symptoms and may help some cognitive and behavioural symptoms.[7] Lecanemab and donanemab are FDA-approved antibody drugs for early Alzheimer’s that target beta-amyloid. In trials in people with early Alzheimer’s or mild cognitive impairment, they slowed cognitive decline in some participants over 18 months and lowered brain amyloid.[19]
Both drugs were tested in large randomised trials that compared them with a placebo.[20][9] On average, people on the drugs declined somewhat more slowly than people on placebo: their scores on a standard dementia rating scale (CDR-SB) worsened by 0.45 points less with lecanemab over 18 months and 0.7 points less with donanemab over 76 weeks.[8][9] They were studied only in people with mild cognitive impairment or mild dementia.[21][20]
- Lecanemab (Leqembi). Clarity AD was an 18-month double-blind Phase 3 trial of 1,795 people aged 50 to 90 with early Alzheimer’s and confirmed amyloid.[20] The CDR-SB score worsened by 1.21 points on lecanemab and 1.66 on placebo, a difference of 0.45 that the authors called moderately less decline, with adverse events.[8] Lecanemab received Accelerated Approval in January 2023 based on amyloid reduction, and FDA converted it to traditional approval in July 2023 after the confirmatory trial (see how FDA drug approval works).[22]
- Donanemab (Kisunla). FDA approved it in July 2024 for people with mild cognitive impairment or mild dementia, with Fast Track, Priority Review and Breakthrough Therapy designations.[21] In TRAILBLAZER-ALZ 2 (1,736 participants), the CDR-SB score worsened by 1.72 points on donanemab and 2.42 on placebo over 76 weeks, a difference of 0.7. Treatment was switched to placebo once amyloid fell enough.[9]
Before prescribing either drug, doctors may order PET scans or a spinal fluid test to check for amyloid.[23] NIA says insurance may cover the drugs only in specific situations, and Medicare Part B covers part of the cost for patients who meet certain criteria.[24]
ARIA and other risks
ARIA usually appears as temporary brain swelling on scans that resolves over time, sometimes with small spots of bleeding. It often causes no symptoms, but serious and life-threatening events can occur, and both drugs carry a boxed warning for ARIA.[10] In Clarity AD, 12.6% of lecanemab participants had ARIA with swelling or fluid (ARIA-E) and 26.4% had infusion-related reactions.[25] In TRAILBLAZER-ALZ 2, ARIA-E occurred in 24.0% of donanemab participants versus 2.1% on placebo. Three deaths on donanemab and one on placebo were considered treatment related.[26]
People with two copies of the ApoE ε4 gene variant have a higher rate of ARIA, including serious ARIA. The labels say ApoE ε4 testing should be done before treatment to inform that risk.[27] Anticoagulant use was linked to more brain haemorrhages on lecanemab than on placebo, and the label advises caution in people taking anticoagulants.[28]
For how trials like Clarity AD and TRAILBLAZER-ALZ 2 are designed and read, see the clinical trials explainer. Questions about eligibility, monitoring scans and side effects are for the treating clinician.
Read next
Next in the crash course
ALS explained: symptoms, diagnosis, treatment and research in 2026
A plain guide to ALS (Lou Gehrig's disease): what happens in the body, who gets it, how it is diagnosed, the approved drugs and the 2026 research news.
Questions readers ask
What is the difference between Alzheimer's and dementia?
Dementia is the general loss of memory, thinking and daily functioning. Alzheimer's disease is its most common cause in older adults. WHO says 57 million people were living with dementia worldwide in 2021.[2][11]
Can a blood test diagnose Alzheimer's?
Not on its own. FDA cleared the Lumipulse blood test in May 2025 for adults 55 and over with symptoms, seen in specialised care, and the Elecsys pTau181 test for primary care later that year. FDA says Lumipulse is not a screening or stand-alone diagnostic test, and NIA says blood test results alone should not be used to diagnose dementia.[5][17][6][14]
How much do lecanemab and donanemab help?
In their Phase 3 trials, the CDR-SB dementia rating worsened by 0.45 points less than placebo over 18 months with lecanemab, and by 0.7 points less over 76 weeks with donanemab. The lecanemab authors described this as moderately less decline. The drugs were studied only in people with mild cognitive impairment or mild dementia.[8][9][21]
What is ARIA?
Amyloid-related imaging abnormalities are a side effect of anti-amyloid drugs. They usually appear as temporary brain swelling on scans, sometimes with small bleeds, and often cause no symptoms, but serious and life-threatening events can occur. Both drugs carry a boxed warning for ARIA.[10][25][26]
Why do doctors test for the ApoE4 gene before treatment?
People with two copies of the ApoE ε4 variant have a higher rate of ARIA, including serious ARIA, and the prescribing information says ApoE ε4 testing should be done before treatment to inform that risk.[27]
Sources
· 28 claims from 7 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
Alzheimer's disease is a progressive brain disorder that slowly destroys memory and thinking skills and eventually the ability to carry out simple tasks; symptoms usually first appear later in life. confirmedas of 2026-11-07
- Alzheimer's Disease Fact Sheet · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease · US Food and Drug Administration · Primary source · 2025-05-16 (retrieved 2026-11-07)
- [2]
The National Institute on Aging says estimates vary but more than 6 million Americans, most aged 65 or older, may have Alzheimer's; it is the seventh leading cause of death in the US and the most common cause of dementia in older adults. confirmedas of 2026-11-07
- Alzheimer's Disease Fact Sheet · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- Alzheimer's Disease Fact Sheet · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- [3]
Amyloid plaques and tau tangles are still considered main features of Alzheimer's, along with the loss of connections between neurons. confirmedas of 2026-11-07
- Alzheimer's Disease Fact Sheet · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- Alzheimer's Disease Fact Sheet · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- [4]
To diagnose Alzheimer's, doctors may take a history, test memory, attention and language, order standard lab tests to rule out other causes, measure Alzheimer's-related proteins in cerebrospinal fluid, and use CT, MRI or PET brain scans. confirmedas of 2026-11-07
- How Is Alzheimer's Disease Diagnosed? · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- How Is Alzheimer's Disease Diagnosed? · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- How Is Alzheimer's Disease Diagnosed? · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- [5]
On 16 May 2025 FDA cleared the first blood test used in diagnosing Alzheimer's, Fujirebio's Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, for adults 55 and older with signs and symptoms of the disease. confirmedas of 2026-11-07
- FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease · US Food and Drug Administration · Primary source · 2025-05-16 (retrieved 2026-11-07)
- FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease · US Food and Drug Administration · Primary source · 2025-05-16 (retrieved 2026-11-07)
- [6]
On 8 October 2025 FDA cleared Roche's Elecsys pTau181 blood test to aid the initial assessment of people aged 55 and older with cognitive decline; trade press, reporting Roche's announcement, described it as the first blood-based Alzheimer's biomarker test for use in primary care. confirmedas of 2026-11-14
- 510(k) clearance letter and summary, K252163: Elecsys Phospho-Tau (181P) Plasma · US Food and Drug Administration · Primary source · 2025-10-08 · Indications for Use; clearance letter dated October 8, 2025 (K252163) (retrieved 2026-11-14)
- Blood-Based P-Tau181 Testing for Alzheimer's Pathology Now Cleared by the FDA for the Primary Care Setting · Practical Neurology · Secondary source · 2025-11-04 (retrieved 2026-11-07)
- FDA Clears Roche's Elecsys pTau181 Test for Ruling Out Alzheimer-Related Amyloid Pathology · NeurologyLive · Secondary source · 2025-10-14 (retrieved 2026-11-07)
- [7]
No known treatment cures Alzheimer's; cholinesterase inhibitors such as donepezil, rivastigmine and galantamine are prescribed for mild to moderate symptoms and may help some cognitive and behavioural symptoms. confirmedas of 2026-11-07
- How Is Alzheimer's Disease Treated? · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- How Is Alzheimer's Disease Treated? · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- [8]
In Clarity AD the CDR-SB dementia score worsened by 1.21 points on lecanemab and 1.66 on placebo over 18 months, a difference of 0.45 points that the authors called moderately less decline, with adverse events. confirmedas of 2026-11-07
- Lecanemab in Early Alzheimer's Disease (PubMed abstract) · New England Journal of Medicine (van Dyck et al.) · Primary source · 2022-11-29 · Abstract, Results (retrieved 2026-11-07)
- Lecanemab in Early Alzheimer's Disease (PubMed abstract) · New England Journal of Medicine (van Dyck et al.) · Primary source · 2022-11-29 · Abstract, Conclusions (retrieved 2026-11-07)
- [9]
In TRAILBLAZER-ALZ 2 (1,736 participants), the CDR-SB score worsened by 1.72 points on donanemab and 2.42 on placebo over 76 weeks in the combined population, a difference of 0.7 points; treatment was switched to placebo once amyloid fell enough. confirmedas of 2026-11-07
- Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial (PubMed abstract) · JAMA (Sims et al.) · Primary source · 2023-07-17 · Abstract, Results (retrieved 2026-11-07)
- Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial (PubMed abstract) · JAMA (Sims et al.) · Primary source · 2023-07-17 · Abstract, Results (retrieved 2026-11-07)
- FDA approves treatment for adults with Alzheimer's disease · US Food and Drug Administration · Primary source · 2024-07-02 (retrieved 2026-11-07)
- [10]
ARIA usually appears as temporary brain swelling on scans that resolves over time, sometimes with small spots of bleeding; it often causes no symptoms, but serious and life-threatening events can occur, and both drugs carry a boxed warning for ARIA. confirmedas of 2026-11-07
- FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval · US Food and Drug Administration · Primary source · 2023-07-06 (retrieved 2026-11-07)
- FDA approves treatment for adults with Alzheimer's disease · US Food and Drug Administration · Primary source · 2024-07-02 (retrieved 2026-11-07)
- FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval · US Food and Drug Administration · Primary source · 2023-07-06 (retrieved 2026-11-07)
- [11]
WHO says 57 million people were living with dementia worldwide in 2021, with nearly 10 million new cases a year, and Alzheimer disease is the most common form of dementia. confirmedas of 2026-11-07
- Dementia - fact sheet · World Health Organization · Primary source · Key facts (retrieved 2026-11-07)
- Dementia - fact sheet · World Health Organization · Primary source · Key facts (retrieved 2026-11-07)
- Dementia - fact sheet · World Health Organization · Primary source · Key facts (retrieved 2026-11-07)
- [12]
WHO says dementia is more common after 65 but not an inevitable part of ageing, and lists risk factors including high blood pressure, diabetes, obesity, depression, hearing and vision loss, smoking, harmful alcohol use, physical inactivity and social isolation. confirmedas of 2026-11-07
- Dementia - fact sheet · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
- Dementia - fact sheet · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
- Dementia - fact sheet · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
- [13]
The same tests can find other causes of memory problems, such as stroke, tumours, sleep problems, medication side effects or infection, some of which may be treatable and possibly reversible. confirmedas of 2026-11-07
- How Is Alzheimer's Disease Diagnosed? · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- [14]
Before the early 2000s Alzheimer's could only be confirmed at autopsy; biomarker tests now show signs of the disease in living people, but NIA says blood test results alone should not be used to diagnose dementia. confirmedas of 2026-11-07
- How Is Alzheimer's Disease Diagnosed? · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- How Is Alzheimer's Disease Diagnosed? · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- [15]
Amyloid PET scans can show plaques, often years before symptoms, but FDA notes they are costly and time-consuming and expose patients to radiation. confirmedas of 2026-11-07
- FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease · US Food and Drug Administration · Primary source · 2025-05-16 (retrieved 2026-11-07)
- FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease · US Food and Drug Administration · Primary source · 2025-05-16 (retrieved 2026-11-07)
- [16]
In the 499-sample study FDA reviewed, 91.7% of people with a positive Lumipulse result had amyloid plaques on PET or CSF testing, 97.3% with a negative result had no plaques, and under 20% got an indeterminate result. confirmedas of 2026-11-07
- FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease · US Food and Drug Administration · Primary source · 2025-05-16 (retrieved 2026-11-07)
- FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease · US Food and Drug Administration · Primary source · 2025-05-16 (retrieved 2026-11-07)
- FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease · US Food and Drug Administration · Primary source · 2025-05-16 (retrieved 2026-11-07)
- [17]
FDA says the Lumipulse test is for patients seen in specialised care with signs of cognitive decline, is not a screening or stand-alone diagnostic test, and carries a risk of false positive and false negative results. confirmedas of 2026-11-07
- FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease · US Food and Drug Administration · Primary source · 2025-05-16 (retrieved 2026-11-07)
- FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease · US Food and Drug Administration · Primary source · 2025-05-16 (retrieved 2026-11-07)
- FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease · US Food and Drug Administration · Primary source · 2025-05-16 (retrieved 2026-11-07)
- [18]
Roche reported that in a 312-person study the Elecsys pTau181 test had a 97.9% negative predictive value for ruling out Alzheimer's pathology in a low-prevalence, early-stage population like primary care. confirmedas of 2026-11-07
- Blood-Based P-Tau181 Testing for Alzheimer's Pathology Now Cleared by the FDA for the Primary Care Setting · Practical Neurology · Secondary source · 2025-11-04 (retrieved 2026-11-07)
- 510(k) clearance letter and summary, K252163: Elecsys Phospho-Tau (181P) Plasma · US Food and Drug Administration · Primary source · 2025-10-08 · 510(k) summary, clinical tests (312 participants reflective of primary care) (retrieved 2026-11-14)
- FDA Clears Roche's Elecsys pTau181 Test for Ruling Out Alzheimer-Related Amyloid Pathology · NeurologyLive · Secondary source · 2025-10-14 (retrieved 2026-11-07)
- [19]
Lecanemab and donanemab are FDA-approved antibody drugs for early Alzheimer's that target beta-amyloid; in trials in people with early Alzheimer's or mild cognitive impairment they slowed cognitive decline in some participants over 18 months and lowered brain amyloid. confirmedas of 2026-11-07
- How Is Alzheimer's Disease Treated? · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- How Is Alzheimer's Disease Treated? · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- [20]
Clarity AD, the lecanemab Phase 3 trial, was an 18-month double-blind trial of 1,795 people aged 50 to 90 with early Alzheimer's and confirmed amyloid. confirmedas of 2026-11-07
- Lecanemab in Early Alzheimer's Disease (PubMed abstract) · New England Journal of Medicine (van Dyck et al.) · Primary source · 2022-11-29 · Abstract, Methods (retrieved 2026-11-07)
- Lecanemab in Early Alzheimer's Disease (PubMed abstract) · New England Journal of Medicine (van Dyck et al.) · Primary source · 2022-11-29 · Abstract, Results (retrieved 2026-11-07)
- [21]
FDA approved donanemab (Kisunla) for Alzheimer's in July 2024, for people with mild cognitive impairment or mild dementia, the population studied in trials; the application had Fast Track, Priority Review and Breakthrough Therapy designations. confirmedas of 2026-11-07
- FDA approves treatment for adults with Alzheimer's disease · US Food and Drug Administration · Primary source · 2024-07-02 (retrieved 2026-11-07)
- FDA approves treatment for adults with Alzheimer's disease · US Food and Drug Administration · Primary source · 2024-07-02 (retrieved 2026-11-07)
- FDA approves treatment for adults with Alzheimer's disease · US Food and Drug Administration · Primary source · 2024-07-02 (retrieved 2026-11-07)
- [22]
Lecanemab (Leqembi) received Accelerated Approval in January 2023 based on its effect on amyloid plaques, then FDA converted it to traditional approval on 6 July 2023 after a confirmatory trial verified clinical benefit. confirmedas of 2026-11-07
- FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval · US Food and Drug Administration · Primary source · 2023-07-06 (retrieved 2026-11-07)
- FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval · US Food and Drug Administration · Primary source · 2023-07-06 (retrieved 2026-11-07)
- [23]
Before prescribing lecanemab or donanemab, doctors may order PET scans or a cerebrospinal fluid test to check for amyloid in the brain. confirmedas of 2026-11-07
- How Is Alzheimer's Disease Treated? · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- [24]
NIA says insurance may cover the anti-amyloid drugs only in specific situations, and Medicare Part B covers part of the cost for patients who meet certain medical criteria. confirmedas of 2026-11-07
- How Is Alzheimer's Disease Treated? · National Institute on Aging (NIH) · Primary source (retrieved 2026-11-07)
- [25]
In Clarity AD, 26.4% of lecanemab participants had infusion-related reactions and 12.6% had amyloid-related imaging abnormalities with oedema or effusions (ARIA-E). confirmedas of 2026-11-07
- Lecanemab in Early Alzheimer's Disease (PubMed abstract) · New England Journal of Medicine (van Dyck et al.) · Primary source · 2022-11-29 · Abstract, Results (retrieved 2026-11-07)
- [26]
In TRAILBLAZER-ALZ 2, ARIA with oedema or effusion occurred in 24.0% of donanemab participants (52 with symptoms) versus 2.1% on placebo, and three deaths on donanemab and one on placebo were considered treatment related. confirmedas of 2026-11-07
- Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial (PubMed abstract) · JAMA (Sims et al.) · Primary source · 2023-07-17 · Abstract, Results (retrieved 2026-11-07)
- Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial (PubMed abstract) · JAMA (Sims et al.) · Primary source · 2023-07-17 · Abstract, Results (retrieved 2026-11-07)
- [27]
People with two copies of the ApoE ε4 gene variant have a higher rate of ARIA, including serious ARIA, and the labels say ApoE ε4 testing should be done before treatment to inform that risk. confirmedas of 2026-11-07
- FDA approves treatment for adults with Alzheimer's disease · US Food and Drug Administration · Primary source · 2024-07-02 (retrieved 2026-11-07)
- FDA approves treatment for adults with Alzheimer's disease · US Food and Drug Administration · Primary source · 2024-07-02 (retrieved 2026-11-07)
- [28]
Anticoagulant use was associated with more brain haemorrhages in people taking lecanemab than on placebo, and the label advises caution in people on anticoagulants. confirmedas of 2026-11-07
- FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval · US Food and Drug Administration · Primary source · 2023-07-06 (retrieved 2026-11-07)
- FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval · US Food and Drug Administration · Primary source · 2023-07-06 (retrieved 2026-11-07)
Revision history (2)
- Sourced the Elecsys pTau181 clearance and its negative predictive value to FDA's 510(k) record (K252163).
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Apr 30, 2027.
Cite this page
"Alzheimer's disease explained: diagnosis, blood tests and new drugs." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/alzheimers-disease-explained
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.